Implantation: Intramuscular or Subcutaneous, Rabbit - 13 Weeks (GLP)

Implantation asks what the tissue does around your device once it is in place. Solid samples are implanted by the intramuscular or subcutaneous route, recovered after 13 weeks, and the test sites are scored histologically against control sites to derive an irritation ranking.

SKU: GRK-4007-03X
Availability:
Price: Call for pricing

When this test applies

Required for implanted devices and for devices contacting breached or compromised tissue, under ISO 10993-1:2025. The intramuscular or subcutaneous route represents soft-tissue contact; devices contacting bone are assessed by the bone route instead. The 13-week timepoint characterises the subchronic response, by which point the capsule around the implant has matured and the picture is closer to steady state.

When to run it

Late, and only once the material and its manufacturing process are locked. Implantation is the longest and most expensive study in the battery, and a formulation change after the implants go in means starting over. Your biological evaluation plan should settle which timepoints the device category actually requires before any of them are commissioned.

What a pass tells you

That the histological response at the test sites, scored against the control sites per ISO 10993-6 Annex E, produced an irritation ranking of 2.9 or less — classed as a non-irritant over a 13 weeks implantation period by this route.

What it does not tell you

Nothing about the response at a different timepoint or by a different route. A 13-week result is not a substitute for 26 weeks where the device is permanent, and it says nothing about the acute response the 2-week study characterises. It also says nothing about systemic effects, genotoxicity or sensitization, each of which is a separate endpoint.

Method

Testing per ISO 10993-6:2016 in the rabbit. Solid samples are implanted directly — there is no extraction step — with sample geometry prepared to the dimensions ISO 10993-6 specifies for the intramuscular or subcutaneous route. After the 13 weeks implantation period the test and control sites are explanted, processed histologically and reviewed by a pathologist, and scored to derive an irritation ranking per Annex E.

Where it runs

This method is internationally sourced. The laboratory is ISO/IEC 17025 accredited and GLP certified, and the report is issued under Groenakker cover, in Groenakker’s report template or in your document template on request at no extra cost.

Usually ordered alongside

Cytotoxicity, sensitization and irritation as the baseline battery, and usually another timepoint in the same programme. Where the device contacts bone, the bone-route studies apply instead of, or in addition to, these.

Products specifications
SubcontractedYes
StandardsISO 10993-6:2016
EndpointLocal Effects of Implantation
Method detail
Test systemIn vivo - rabbit
MethodImplantation, intramuscular or subcutaneous, 13 weeks implantation period
ExtractionSolid samples implanted; no extraction. Sample geometry prepared to the dimensions in ISO 10993-6 for the intramuscular or subcutaneous route.
Acceptance criteriaPer ISO 10993-6 Annex E, the test sites are scored histologically against the control sites and an irritation ranking is derived; a difference of 2.9 or less is classed as a non-irritant. The 13 weeks implantation period is followed by explantation, histological processing and pathology review.
DeliverableGLP-compliant final report with raw data, issued in Groenakker’s report template or in your document template on request at no extra cost, under Groenakker’s ISO 13485:2016 certified quality system.
Testing locationInternational (OUS)
*
*
*